<DOC>
	<DOCNO>NCT00661921</DOCNO>
	<brief_summary>The purpose study investigate effect block IL-1 signal AMG 108 type 2 diabetes mellitus patient glycemic control , measure change HbA1c baseline end treatment ( EOT ) .</brief_summary>
	<brief_title>A Randomized Double Blind , Placebo Controlled Trial With AMG 108 Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Diagnosis T2DM ≥ 3 month time randomization HbA1c 7.0 9.5 % ( inclusive ) screen ≥ 18 year age time randomization BMI ≥ 25 kg/m2 ≤ 45 kg/m2 screening , , per patient selfreport , follow regular weight maintenance reduction diet management diabetes least 4 week prior randomization Fasting plasma glucose ≤ 240 mg/dL ( 13.3 mmol/L ) 2 determination screen ( sample take least 1 day apart ) No new therapy treatment elevate blood pressure dyslipidemia , use weight loss medication ( counter prescription ) , initiation prescribe weight management exercise program within 4 week randomization Subject able willing comply study 's visit requirement History type 1 insulindependent diabetes Significant sign symptom uncontrolled hyperglycemia ( ie , polyuria , polydypsia , polyphagia ) , opinion investigator History significant weight gain loss ( +/ 5 % ) 4 week randomization Triglycerides ≥ 400 mg/dL ( 4.5 mmol/L ) and/or total cholesterol ≥340 mg/dL ( 8.7 mmol/L ) screen Currently receive receive within 60 day prior screen antidiabetic pharmaceutical therapy ( eg , insulin ) metformin and/or sulfonylurea . If receive metformin sulfonylurea , dose must stable ≥ 60 day . Uncontrolled hypertension define diastolic pressure &gt; 95 mmHg and/or systolic &gt; 170 mmHg screen Hepatic function test ( alanine aminotranferase ( ALT ) , aspartate aminotransferase ( AST ) , alkaline phosphatase , total bilirubin ) result screen &gt; 2 time upper limit normal central laboratory White blood cell count &lt; 3000 / μL , absolute neutrophil count ( ANC ) &lt; 2500 / μL , platelet count &lt; 125,000 / μL screen Any significant inflammatory , rheumatologic , systemic autoimmune disease opinion investigator Evidence active infection , recent infection , chronic infection , require treatment antiinfectives , hospitalization IV antibiotic within 4 week prior randomization Active latent Mycobacterium tuberculosis infection define know positive PPD chest xray finding failure complete treatment appropriate chemoprophylaxis , exposure person active tuberculosis within 6 month prior randomization Existence nonhealing wound ulcer Known positive hepatitis B surface antigen ( HbsAg ) , hepatitis C virus ( HCV ) human immunodeficiency virus ( HIV ) Estimated GFR ( eGFR ) screen &lt; 30 mL/min calculate via MDRD equation ( Modification Diet Renal Disease study group ) Clinical evidence current malignancy , follow exception : basal squamous cell carcinoma skin , cervical intraepithelial neoplasia , prostate cancer ( stable localize disease , life expectancy &gt; 3 year ) ; receive receive chemotherapy and/or radiation therapy treatment malignancy within 6 month prior randomization Clinically significant cardiovascular disease ( eg , heart failure New York Heart Association [ NYHA ] class 3 4 ) , hematological abnormality , asthma , chronic obstructive pulmonary disease ( eg , require oral IV steroid ) , opinion investigator Receipt biologic immunosuppressive therapy ( experimental commercial ) , include anakinra ( Kineret® ) tumor necrosis factor ( TNF ) block agent ( eg , etanercept infliximab ) , live vaccine , within 3 month randomization Previously receive AMG 108 Subject evidently pregnant ( eg , positive human chorionic gonadotropin [ HCG ] test ) , breast feeding , childbearing potential use adequate contraceptive precaution , determine investigator Subject currently enrol yet complete least 30 day since end investigational device drug study ( ) , subject receive investigational agent ( ) Subject kind condition ( eg , psychiatric illness ) situation , investigator 's opinion , compromise ability subject give write informed consent , may put subject significant risk , may confound study result , may interfere significantly subject 's participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>AMG 108</keyword>
	<keyword>HbA1C</keyword>
	<keyword>glucose</keyword>
	<keyword>metformin</keyword>
	<keyword>sulfonylurea</keyword>
	<keyword>IL-1 Inhibitor</keyword>
	<keyword>biologic</keyword>
	<keyword>subcutaneous injection</keyword>
</DOC>